15ml-carton (15ml Carton)
Irinotecan Hydrochloride Injection, Solution
Product Images NDC 67184-0512
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 11 technical images submitted to the FDA as part of the official labeling for Irinotecan Hydrochloride (NDC 67184-0512). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Qilu Pharmaceutical Co., Ltd., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
15ml-container (15ml Container)
Irinotecan Hydrochloride Injection is a cytotoxic agent that is intended for intravenous use after dilution. This medication comes in a 300 mg/15 mL concentration (20 mg/mL) and is for single-use only. Any unused portion must be discarded. This medication should be stored at a temperature range of 20° to 25°C (68° to 77°F), with excursions allowed to 15° to 30°C (59° to 86°F), and it should be protected from both light and freezing. If you need more information about Irinotecan Hydrochloride Injection, please see the accompanying prescribing information.*
2ml-carton (2ml Carton)
2ml-container (2ml Container)
This is a description for a medication called Irinotecan Hydrochloride. It is an injectable cytotoxic agent used for intravenous use only. The medication needs to be diluted before use and has an expiry date of Rev. 312016. The information is provided by a pharmaceutical company named Hainan located at Ko 5757, Coine.*
5ml-carton (5ml Carton)
5ml-container (5ml Container)
This is a description of a prescription drug, Irinotecan Hydrochloride, which is available in the form of an injection. It is manufactured by Qilu Pharmaceutical (Hainan) Co., Ltd. in China and is meant for intravenous use only. The drug must be diluted before use, and caution must be exercised as it is a cytotoxic agent. The dosage instructions are to be obtained from the accompanying prescribing information, and the drug should be stored at a temperature between 20°C and 25°C, with excursions permitted to 15°C to 30°C. The drug must be protected from light and freezing, and the carton should be retained. The lot number for this product is not provided.*
Figure 1
The text appears to be an incomplete figure caption for a survival graph in Study 1. It compares the survival rates of patients receiving First-Line Irinotecan/s-FUILV versus 5-FULLV, possibly in the treatment of cancer. The graph shows a time period of 42 months, with survival rates plotted on the y-axis. There is a reference to a statistical test called the "Jog-rank test", which might have been used to analyze the data.*
Figure 2
The text seems to be a part of a scientific study or article describing the survival rates of patients treated with Irinotecan/5-FUILV compared to 5-FUILV alone in Study 2. The figure shows a graph with two lines representing the survival rates of patients treated with Irinotecan/s-FU/LV and 5-FULV. The log-rank test may have been used to compare the survival curves.*
Figure 3. Survival Second-line Irinotecan Vs Best Supportive Care (bsc) Study 7 (Figure 3)
The text provided seems to be a table showing the survival rate in a study comparing second-line Irinotecan treatment with Best Supportive Care (BSC). The table shows data for Study 7, with 188 participants, having a median follow-up of 13 months. The survival rates are presented as a percentage, with Irinotecan showing a higher rate of survival compared to BSC. The median survival for Irinotecan is noted as 92 months, with the corresponding values for BSC being 65 and 21.*
Figure 4. Survival Second-line Irinotecan Vs Infusional 5-fu Study 8 (Figure 4)
This is a comparison of survival rates between two different chemotherapy drugs for second-line treatment. The drugs are Irinotecan and Infusion 5-FU, with 127 patients receiving Irinotecan and 129 patients receiving Infusion 5-FU. The median follow-up time was 15 months with a median survival of 108 months for Irinotecan and 85 months for Infusion 5-FU. The logrank test showed a significant difference in survival rates with a p-value of 0.035.*
Irinotecan Hydrochloride Structural Formula (Irinotecan Hydrochloride)
* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.
